Agree with focussing on the data. As part of its review, the FiftyOne Capital report takes a look at the data from a study in 2005 (Ghosh). The most important takeaway for me is that the Ghosh study would have met the primary endpoints for our P2 trial, and we are providing twice the dosage of the that study!! The effect of this can be seen already in the SAS results that have been released (similar dosage to our P2) which are much better than the (already significant) Ghosh data. The 2005 paper is at this link and worth a read for data driven investors............
https://www.sciencedirect.com/science/article/pii/S0011393X05001311
Agree with focussing on the data. As part of its review, the...
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.0¢ |
Change
-0.010(3.57%) |
Mkt cap ! $82.30M | |||
| Open | High | Low | Value | Volume |
| 28.0¢ | 28.0¢ | 26.5¢ | $281.4K | 1.024M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3499 | 27.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.0¢ | 161588 | 8 |
View Market Depth
| Last trade - 16.10pm 21/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |
